Imed Pharmaceuticals (India) Private Limited - Charges

Every charge - open or closed - that lenders have registered against Imed Pharmaceuticals (India) Private Limited, with the most recent acti…

2008-07-15 Hubli, Karnataka Active Unlisted Active Non-Compliant
Share
View plans
IP Imed Pharmaceuticals (India) Private Limited
Open charges
2
8.75 cr
Closed charges
0
0.00
Total
2
8.75 cr
Open vs closed
Top charge holders (by amount)
Top lenders
#LenderChargesAmount
1 Krishnakumar G. Agrawal On Behalf Of Kar… 1 5.00 cr
2 Axis Bank Limited 1 3.75 cr
All charges (2) - latest first
Charge ID Charge holder Created Modified Satisfied Amount Status
10394589 Axis Bank Limited 20 Dec 2012 - - 3.75 cr Open
10380225 Krishnakumar G. Agrawal On Behalf Of Kare Labs Private Limited 21 Aug 2012 - - 5.00 cr Open
Frequently Asked Questions - Charges & borrowings
What do "charges" mean for Imed Pharmaceuticals (India) Private Limited?
Charges are registrable security interests-typically loans or credit facilities-filed with MCA against Imed Pharmaceuticals (India) Private Limited (CIN: U24200KA2008PTC047159). They indicate assets or undertakings pledged to lenders or charge holders.
What is the difference between open and closed charges?
Open charges are active or not yet fully discharged; closed (or satisfied) charges are recorded as settled or released. Counts and amounts on this page follow the statuses shown in the charge list.
How should I read the open vs closed amounts?
Open and closed amounts summarise registrable amounts by status for quick comparison; individual rows may show charge-specific amounts, holders, and dates for verification.
Who are the "top lenders" or charge holders?
Top lenders group charge holders by bank or institution name and approximate exposure so you can see which lenders appear most prominently for Imed Pharmaceuticals (India) Private Limited.
Where can I cross-check financial or ownership context?
Pair this Charges view with the Financial and Ownership sections on this company's V1 profile for loans in financial statements and cap table context alongside MCA charge filings.